These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8531241)

  • 21. Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study.
    Fujii E; Kimura K; Mizoguchi K; Kato A; Takanashi H; Itoh Z; Omura S; Suzuki M
    Toxicol Appl Pharmacol; 2008 Apr; 228(1):1-7. PubMed ID: 18355581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of potential human carcinogenicity of the synthetic monomer ethyl acrylate.
    Williams GM; Iatropoulos MJ
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):6-15. PubMed ID: 18930102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of in vivo short-term studies on carcinogenic risk assessment.
    Takahashi M
    J Toxicol Sci; 1995 Sep; 20(4):465-7. PubMed ID: 8531243
    [No Abstract]   [Full Text] [Related]  

  • 24. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent bioassay results on coal tars and benzo(a)pyrene: implications for risk assessment.
    Gaylor DW; Moolgavkar S; Krewski D; Goldstein LS
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):178-9. PubMed ID: 9927566
    [No Abstract]   [Full Text] [Related]  

  • 27. Dietary modulation of the carcinogenicity of the heterocyclic amines.
    Weisburger JH; Rivenson A; Kingston DG; Wilkins TD; Van Tassell RL; Nagao M; Sugimura T; Hara Y
    Princess Takamatsu Symp; 1995; 23():240-50. PubMed ID: 8844815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse.
    Hoivik DJ; Allen JS; Wall HG; Nold JB; Miller RT; Santostefano MJ
    Int J Toxicol; 2005; 24(5):349-56. PubMed ID: 16257854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organochlorine insecticides and mouse liver tumors: an analysis of responses and mechanisms.
    Stevenson DE
    Prog Clin Biol Res; 1990; 331():367-83. PubMed ID: 2179962
    [No Abstract]   [Full Text] [Related]  

  • 30. Forestomach tumor induction by 2,4-hexadienal in F344N rats and B6C3F1 mice.
    Chan PC; Mahler J; Peddada S; Lomnitski L; Nyska A
    Arch Toxicol; 2003 Sep; 77(9):511-20. PubMed ID: 12879212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impacts of chemicals on liver cancer risk.
    Wogan GN
    Semin Cancer Biol; 2000 Jun; 10(3):201-10. PubMed ID: 10936069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promotion of hepatocarcinogenesis in humans and animal models.
    Köhle C; Schwarz M; Bock KW
    Arch Toxicol; 2008 Sep; 82(9):623-31. PubMed ID: 18204979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IPCS framework for analyzing the relevance of a cancer mode of action for humans.
    Boobis AR; Cohen SM; Dellarco V; McGregor D; Meek ME; Vickers C; Willcocks D; Farland W
    Crit Rev Toxicol; 2006; 36(10):781-92. PubMed ID: 17118728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe.
    Van Oosterhout JP; Van der Laan JW; De Waal EJ; Olejniczak K; Hilgenfeld M; Schmidt V; Bass R
    Regul Toxicol Pharmacol; 1997 Feb; 25(1):6-17. PubMed ID: 9056497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
    Nesfield SR; Clarke CJ; Hoivik DJ; Miller RT; Allen JS; Selinger K; Santostefano MJ
    Int J Toxicol; 2005; 24(5):301-11. PubMed ID: 16257850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mode of action considerations in the quantitative assessment of tumour responses in the liver.
    Boobis AR
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):173-9. PubMed ID: 20030633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisiting alternative approaches to the assessment of carcinogenic risk.
    Downes N
    Toxicol Pathol; 2010 Feb; 38(2):324-7. PubMed ID: 20124498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Studies on the origin of carcinogenic nitrosamines in the stomach].
    Sander J; Schweinsberg F; Menz HP
    Hoppe Seylers Z Physiol Chem; 1968 Dec; 349(12):1691-7. PubMed ID: 5707037
    [No Abstract]   [Full Text] [Related]  

  • 39. [Omeprazole long-term therapy: how great is the risk of developing a carcinoid tumor?].
    Koop H
    Z Gastroenterol; 1988 Dec; 26(12):769-71. PubMed ID: 3149827
    [No Abstract]   [Full Text] [Related]  

  • 40. Omeprazole, hypergastrinemia, and gastric carcinoid tumors.
    Freston JW
    Ann Intern Med; 1994 Aug; 121(3):232-3. PubMed ID: 8017751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.